Literature DB >> 9577944

Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.

M Kyriakidis1, F Triposkiadis, J Dernellis, A E Androulakis, P Mellas, G A Kelepeshis, J E Gialafos.   

Abstract

BACKGROUND: Left ventricular (LV) diastolic function and coronary flow are impaired in hypertrophic obstructive cardiomyopathy (HOCM). This study was designed to evaluate the impact of cardiac and circulatory ACE inhibition on such derangements. METHODS AND
RESULTS: Twenty patients with HOCM underwent cardiac ACE inhibition with intracoronary (IC) enalaprilat (0.05 mg/min infused into the left anterior descending coronary artery for 15 minutes) followed by circulatory ACE inhibition with 25 mg sublingual (SL) captopril. Contrast ventriculography, pressure, and coronary flow measurements were performed at baseline, after IC enalaprilat infusion, and 45 minutes after SL captopril. Heart rate was not affected by the respective interventions (75+/-11 versus 76+/-13 versus 75+/-10 bpm; P=NS), whereas mean aortic pressure dropped slightly after IC enalaprilat and significantly after SL captopril (90+/-8 versus 85+/-10 versus 74+/-9 mm Hg; P<.05). Compared with baseline, IC enalaprilat resulted in a decrease in LV end-diastolic pressure (17.6+/-5.9 versus 14.4+/-4.9 mm Hg; P<.05), time constant of isovolumic LV pressure relaxation (tauG) (69+/-9 versus 52+/-10 ms; P<.05), and outflow gradient (45.2+/-6.9 versus 24.4+/-3.7 mm Hg; P<.05) and in an increase in coronary blood flow (107+/-10 versus 127+/-12 mL/min; P<.05) and coronary flow reserve (2.2+/-0.4 versus 2.6+/-0.3; P<.05). After SL captopril, tauG was prolonged (60+/-13 ms; P<.05 versus IC enalaprilat), and LV outflow gradient, coronary blood flow, and coronary flow reserve values returned to baseline (45.5+/-5.3 mm Hg, 107+/-12 mL/min, and 2.2+/-0.5, respectively; P=NS versus baseline).
CONCLUSIONS: Activation of the cardiac renin-angiotensin system contributes to LV diastolic dysfunction as well as to the decreased coronary blood flow and coronary flow reserve in HOCM. Cardiac ACE inhibition restores and circulatory ACE inhibition aggravates the above derangements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577944     DOI: 10.1161/01.cir.97.14.1342

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Medical treatment of hypertrophic cardiomyopathy.

Authors:  M V Sherrid; D Gunsburg; A Sharma
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 2.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

3.  Aging and the brain renin-angiotensin system: relevance to age-related decline in cardiac function.

Authors:  Debra I Diz; Jasmina Varagic; Leanne Groban
Journal:  Future Cardiol       Date:  2008-05

4.  Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study.

Authors:  Mylène Taillefer; Rocky Di Fruscia
Journal:  Can Vet J       Date:  2006-05       Impact factor: 1.008

5.  Exercise training reverses age-induced diastolic dysfunction and restores coronary microvascular function.

Authors:  Kazuki Hotta; Bei Chen; Bradley J Behnke; Payal Ghosh; John N Stabley; Jeremy A Bramy; Jaime L Sepulveda; Michael D Delp; Judy M Muller-Delp
Journal:  J Physiol       Date:  2017-05-23       Impact factor: 5.182

6.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

Review 7.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

8.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 9.  Hypertrophic cardiomyopathy: a review.

Authors:  Brian A Houston; Gerin R Stevens
Journal:  Clin Med Insights Cardiol       Date:  2015-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.